FY2026 Earnings Estimate for Zoetis Issued By Zacks Research

Zoetis Inc. (NYSE:ZTS) – Zacks Research dropped their FY2026 earnings estimates for Zoetis in a report released on Thursday, March 6th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of $6.55 for the year, down from their prior estimate of $6.97. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q4 2026 earnings at $1.66 EPS.

Other equities research analysts have also issued research reports about the company. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Finally, Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $215.90.

Zoetis Stock Up 0.8 %

Shares of ZTS stock opened at $171.70 on Monday. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The firm has a market capitalization of $76.89 billion, a PE ratio of 31.39, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock’s 50-day simple moving average is $166.91 and its 200-day simple moving average is $176.66.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion.

Institutional Trading of Zoetis

Institutional investors have recently modified their holdings of the stock. Mission Wealth Management LP boosted its holdings in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares during the last quarter. Hancock Whitney Corp lifted its position in shares of Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares in the last quarter. Strategy Asset Managers LLC boosted its stake in shares of Zoetis by 3.5% in the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after acquiring an additional 62 shares during the last quarter. VeraBank N.A. increased its position in shares of Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares in the last quarter. Finally, HUB Investment Partners LLC raised its stake in Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s dividend payout ratio is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.